Cu-67 SAR-bisPSMA

Cu-67 SAR-bisPSMA is a targeted copper theranostic radiopharmaceutical consisting of two prostate-specific membrane antigen (PSMA)–binding motifs linked to a sarcophagine (SAR) chelator and radiolabeled with the beta- and Auger electron–emitting isotope copper-67 to deliver cytotoxic radiation to PSMA-expressing tumors.[12][7][9] Developed by Clarity Pharmaceuticals as the therapeutic counterpart to the PET imaging agent 64Cu-SAR-bisPSMA, it exploits dual PSMA ligands to increase tumor uptake and retention compared with first-generation PSMA ligands, enabling highly selective irradiation of PSMA-positive metastatic lesions while sparing normal tissues.[7][9][10] The drug is being investigated primarily for metastatic castration-resistant prostate cancer (mCRPC), where it has received FDA Fast Track designation for PSMA-positive mCRPC after prior androgen receptor pathway inhibitor therapy and is under evaluation in phase 1/2 theranostic trials that pair 64Cu-SAR-bisPSMA imaging with Cu-67 SAR-bisPSMA therapy.[3][5][1][2]

Other names

copper Cu 67 SAR-bisPSMAcopper-67 SAR-bisPSMAcopper67 SAR-bisPSMAcopper 67 SAR-bisPSMA67Cu-SARbisPSMACu-67-SAR-bisPSMACu67-SAR-bisPSMACu 67-SAR-bisPSMAcopper Cu 67 abefolastat tesaroxetan